Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 126

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 126
---
 price of their stock have
been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business
concerns, which could seriously harm our business.

76

Special note regarding forward-looking statements This prospectus includes forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future operating results and financial position, our business strategy and plans, market growth, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “forecast,” “could,” “plan,” “potential,” “predict,” “seek,” “target,” “should,” “would,” or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. Forward-looking statements contained in this prospectus include, statements about:

| • |     | the level of demand for any of our products, which may vary significantly; |

| • |     | our ability to increase the adoption of our products in the prenatal and oncology markets and in large healthcare systems; |

| • |     | our ability to generate persuasive clinical validity and utility evidence; |

| • |     | our ability to expand our portfolio of molecular diagnostic tests; |

| • |     | our ability to use AI effectively and efficiently; |

| • |     | our ability to execute our reimbursement strategy and expand coverage of our tests; |

| • |     | our ability to replicate positive results from trials or studies conducted by us or third parties in current or future 
 trials or studies;                                                                                                     |

| • |     | the potential for our UNITY Fetal Antigen CTA to become the first NIPT to have a companion diagnostics indication pending; |

| • |     | the successful completion of Johnson & Johnson’s AZALEA Phase 3 clinical trial; |

| • |     | the implementation of our business model and strategic plans; |

| • |     | the size and growth potential of the total addressable markets for our current and future products and our ability to serve